Insider filing · NAMS
Mayur Ian Somaiya
Chief Financial Officer
profile →
NewAmsterdam Pharma Company N.V.
NAMS · Healthcare · 45 filings in 24 months
ticker →
Mayur Ian Somaiya sold $3.2M of NewAmsterdam Pharma (NAMS)
Executed Jan 20, disclosed Jan 22, 2 days later.
Value, as filed
$3.2M
99,100 sh across 4 lots
Executed
Jan 20
the trade date, as filed
Disclosed
Jan 22
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
MSMayur Ian Somaiya (Chief Financial Officer) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in NewAmsterdam Pharma Company N.V. (NAMS). The largest single filing was $3.2M of NAMS (99,100 sh across 4 lots, as filed), executed Jan 20.
The name
NAMSHealthcare · NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with ca…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Mayur Ian Somaiya in NAMS
NAMSSALE
NewAmsterdam Pharma Company N.V.
$170K5,118 sh × $33.25
Exec Jan 5
Filed Jan 7 · 5:30 PM ET NAMSSALE NewAmsterdam Pharma Company N.V. $1.3M
58,478 sh across 3 lots
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET